

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Post-Effective Amendment No. 1**  
**to**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-275250**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-265832**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-254705**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-236229**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-232106**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-226701**  
**FORM S-8 REGISTRATION STATEMENT NO. 333-218468**  
**UNDER**  
**THE SECURITIES ACT OF 1933**

---

**G1 THERAPEUTICS, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**26-3648180**  
(I.R.S. Employer  
Identification No.)

---

**700 Park Offices Drive, Suite 200**  
**Research Triangle Park, NC 27709**  
(Address of Principal Executive Offices)  
(Zip Code)

**2011 Equity Incentive Plan, as amended**  
**2017 Employee, Director and Consultant Equity Incentive Plan, as amended**  
**2021 Inducement Equity Incentive Plan**  
**Amended and Restated 2021 Inducement Equity Incentive Plan**  
**2021 Sales Force Inducement Equity Incentive Plan**  
**Inducement Stock Option Award to Andrew Perry**  
**Inducement Stock Option Award to Soma Gupta**  
**Inducement Stock Option Award to William C. Roberts**  
**Inducement Stock Option Award to Barclay A. Phillips**  
(Full Titles of the Plans)

**Monica Roberts Thomas, Esq.**  
**General Counsel**  
**G1 Therapeutics, Inc.**  
**700 Park Offices Drive, Suite 200**  
**Research Triangle Park, NC 27709**  
(Name and Address of Agent for Service)

**(919) 213-9835**  
(Telephone Number, Including Area Code, of Agent for Service)

---

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

## DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (the “Post-Effective Amendments”) related to the following Registration Statements on Form S-8 (each a “Registration Statement” and collectively, the “Registration Statements”), is being filed with the Securities and Exchange Commission (the “SEC”) by G1 Therapeutics, Inc. (the “Registrant” or the “Company”) to terminate all offerings under the Registration Statements and to withdraw and remove from registration the shares of the Registrant’s common stock, par value \$0.0001 per share (“Common Stock”), that had been registered under such Registration Statements, together with any and all plan interests and other securities registered thereunder:

- Registration Statement ([File No. 333-218468](#)), filed with the SEC on June 2, 2017, registering (i) 3,807,556 shares of Common Stock under the 2011 Equity Incentive Plan, as amended, and (ii) 1,932,000 shares of Common Stock under the 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”);
- Registration Statement ([File No. 333-226701](#)), filed with the SEC on August 8, 2018, registering (i) 150,000 shares of Common Stock under the Inducement Stock Option Award to Barclay A. Phillips and (ii) 1,066,692 shares of Common Stock under the 2017 Plan, as amended;
- Registration Statement ([File No. 333-232106](#)), filed with the SEC on June 14, 2019, registering 1,096,553 shares of Common Stock under the 2017 Plan, as amended;
- Registration Statement ([File No. 333-236229](#)), filed with the SEC on February 3, 2020, registering 1,096,553 shares of Common Stock under the 2017 Plan, as amended;
- Registration Statement ([File No. 333-254705](#)), filed with the SEC on March 25, 2021, registering (i) 1,096,553 shares of Common Stock under the 2017 Plan, as amended, (ii) 300,000 shares of Common Stock under the Inducement Stock Option Award to Soma Gupta, (iii) 50,000 shares of Common Stock under the Inducement Stock Option Award to William C. Roberts and (iv) 500,000 shares of Common Stock under the 2021 Inducement Equity Incentive Plan;
- Registration Statement ([File No. 333-265832](#)), filed with the SEC on June 24, 2022, registering (i) 1,096,553 shares of Common Stock under the 2017 Plan, as amended, (ii) 500,000 shares of Common Stock under the 2021 Sales Force Inducement Equity Incentive Plan, (iii) 750,000 shares of Common Stock under the Amended and Restated 2021 Inducement Equity Incentive Plan, and (iv) 300,000 shares of Common Stock under the Inducement Stock Option Award to Andrew Perry; and
- Registration Statement ([File No. 333-275250](#)), filed with the SEC on November 1, 2023, registering 1,096,553 shares of Common Stock under the 2017 Plan, as amended.

On September 18, 2024, pursuant to the Agreement and Plan of Merger, dated as of August 6, 2024 (the “Merger Agreement”), by and among the Company, Pharmacosmos A/S, a Danish *Aktieselskab* (“Parent”), and Parent’s indirect wholly owned subsidiary, Genesis Merger Sub, Inc., a Delaware corporation (“Purchaser”), Purchaser merged with and into the Company, with the Company continuing as the surviving corporation and as an indirect wholly owned subsidiary of Parent.

As a result of the consummation of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any securities registered under the Registration Statements that remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Research Triangle Park, State of North Carolina, on September 18, 2024.

G1 THERAPEUTICS, INC.

By: /s/ John W. Umstead V

John W. Umstead V  
Chief Financial Officer

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.